Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Ty800 in Healthy Adults
NCT00269295Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2006
- Primary completion
- Jan 2007
- Modality
- Recombinant Proteins and Enzymes, Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Ty800 in typhoid fever (6 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Safety of Ty800 oral typhoid vaccine. Started Feb 2006; status: completed.
02
Drugs
Ty800
03
Conditions
typhoid fever
Beyond the preview
Go deeper on NCT00269295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269295.